Prevalence of type 2 inflammatory signatures and efficacy of dupilumab in patients with chronic rhinosinusitis with nasal polyps from two phase 3 clinical trials: SINUS‐24 and SINUS‐52. - Bachert, Claus; Khan, Asif H.; Lee, Stella E.; Hopkins, Claire; Peters, Anju T.; Fokkens, Wytske; Praestgaard, Amy; Radwan, Amr; Nash, Scott; Jacob‐Nara, Juby A.; Deniz, Yamo; Rowe, Paul J. (International Forum of Allergy & Rhinology, 2024)